Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease

Gill, Steven S., Patel, Nikunj K., Hotton, Gary R., O'Sullivan, Karen, McCarter, Renée, Bunnage, Martin, Brooks, David J., Svendsen, Clive N. +1 more·2003·Nature Medicine

Cited by (1,000)

Items 601–700 of 1,000

  1. Growth factors and their peptide mimetics for treatment of traumatic brain injury
    Emily A. Atkinson, Rachael Dickman · 2023 · Bioorganic & Medicinal Chemistry
  2. Translating the therapeutic potential of neurotrophic factors to clinical ‘proof of concept’: A personal saga achieving a career-long quest
    Raymond T. Bartus · 2012 · Neurobiology of Disease
  3. Systemically administered neuregulin‐1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease
    Candan Depboylu, Thomas W. Rösler, Anderson de Andrade, Wolfgang Hermann Oertel, Günter U. Höglinger · 2015 · Journal of Neurochemistry
  4. Maximising coverage of brain structures using controlled reflux, convection-enhanced delivery and the recessed step catheter
    Owen Lewis, Max Woolley, David E. Johnson, Julia Fletcher, Johnathan Fenech, Mariusz W. Pietrzyk, Neil U. Barua, Alison S. Bienemann, William Singleton, Samuel Lewin Evans et al. · 2018 · Journal of Neuroscience Methods
  5. Tricyclic antidepressant treatment evokes regional changes in neurotrophic factors over time within the intact and degenerating nigrostriatal system
    Katrina L. Paumier, Caryl E. Sortwell, Lalitha Madhavan, Brian T. Terpstra, Brian F. Daley, Timothy J. Collier · 2015 · Experimental Neurology
  6. mGluR2/3 agonist LY379268, by enhancing the production of GDNF, induces a time-related phosphorylation of RET receptor and intracellular signaling Erk1/2 in mouse striatum
    Valentina Di Liberto, Giuseppa Mudò, Natale Belluardo · 2011 · Neuropharmacology
  7. Quantifying Fluid Infusions and Tissue Expansion in Brain
    Martin Brady, Raghu Raghavan, Zhijian Chen, William C. Broaddus · 2011 · IEEE Transactions on Biomedical Engineering
  8. Combination of CDNF and Deep Brain Stimulation Decreases Neurological Deficits in Late-stage Model Parkinson’s Disease
    Antti Huotarinen, Anna‐Maija Penttinen, Susanne Bäck, Merja H. Voutilainen, Ulrika H. Julku, Petteri T. Piepponen, Pekka T. Männistö, Märt Saarma, Raimo K. Tuominen, Aki Laakso et al. · 2018 · Neuroscience
  9. Dopaminergic innervation of forebrain by ventral mesencephalon in organotypic slice co-cultures: Effects of GDNF
    Juliann D. Jaumotte, Michael J. Zigmond · 2005 · Molecular Brain Research
  10. STEREOTACTIC NEUROSURGERY IN THE UNITED KINGDOM
    Erlick A C Pereira, Alexander L. Green, Dipankar Nandi, Tipu Zahed Aziz · 2008 · Neurosurgery
  11. Smilagenin Protects Dopaminergic Neurons in Chronic MPTP/Probenecid—Lesioned Parkinson’s Disease Models
    He, Xuan, Yang, Shuangshuang, Zhang, Rui, Hou, Lina, Xu, Jianrong, Hu, Yaer, Xu, Rang, Wang, Hao, Zhang, Yongfang · 2019 · Frontiers in Cellular Neuroscience
  12. Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model
    D Yin, You Zhai, Harry E. Gruber, Carlos E. Ibañez, Joan M. Robbins, Adrian P. Kells, Noriyuki Kasahara, John Forsayeth, Douglas J. Jolly, Krys S. Bankiewicz · 2013 · Cancer Gene Therapy
  13. Optimized Quantities of GDNF Overexpressed by Engineered Astrocytes Are Critical for Protection of Neuroblastoma Cells Against 6-OHDA Toxicity
    Roya Safi, Mossa Gardaneh, Yasin Panahi, Nader Maghsoudi, Mohammad Zaefizadeh, Ehsan Gharib · 2011 · Journal of Molecular Neuroscience
  14. Failure of Glial Cell-Line Derived Neurotrophic Factor (GDNF) in Clinical Trials Orchestrated By Reduced NR4A2 (NURR1) Transcription Factor in Parkinson’s Disease. A Systematic Review
    Piniel Alphayo Kambey, Kouminin Kanwore, Abiola Abdulrahman Ayanlaja, Iqra Nadeem, Du Yinzhen, Wokuheleza Buberwa, Wenya Liu, Dianshuai Gao · 2021 · Frontiers in Aging Neuroscience
  15. Chapter 18 Convection-Enhanced Delivery of Liposomes to Primate Brain
    Michal Tadeusz Krauze, John Forsayeth, Dali Yin, Krystof S. Bankiewicz · 2009 · Methods in enzymology on CD-ROM/Methods in enzymology
  16. Pathways towards an effective immunotherapy for Parkinson’s disease
    Jessica A.L. Hutter-Saunders, Rodney Lee Mosley, Howard Eliot Gendelman · 2011 · Expert Review of Neurotherapeutics
  17. 2‐DE profiling of GDNF overexpression‐related proteome changes in differentiating ST14A rat progenitor cells
    Raimund Hoffrogge, Susanne Beyer, Rayk Hübner, Stefan Mikkat, Eilhard Mix, Christian Scharf, Ulf Schmitz, Stefan Pauleweit, Matthias Berth, Igor Z. Zubrzycki et al. · 2006 · PROTEOMICS
  18. Alzheimer'S Disease: Advances In Genetics, Molecular And Cellular Biology
    Sangram S. Sisodia, Rudolph E. Tanzi · 2007
  19. The Future of Cell-Based Transplantation Therapies for Neurodegenerative Disorders
    Stanley E. Lazic, Roger A. Barker · 2003 · Stem Cells and Development
  20. Hypothalamic rAAV-mediated GDNF gene delivery ameliorates age-related obesity
    Nihal Tümer, Philip J. Scarpace, M.Devrim Doğan, Christopher S. Broxson, Michael Edwin Matheny, David M. Yurek, Carmen S. Peden, Corinna Bürger, Nicholas Muzyczka, Ronald J. Mandel · 2005 · Neurobiology of Aging
  21. Advances in Gene Therapy for Movement Disorders
    Hideki Mochizuki, Toru Yasuda, M. Maral Mouradian · 2008 · Neurotherapeutics
  22. Adult Versus Embryonic Stem Cells: Treatments
    Shane D. B. Smith, William B. Neaves, Steven L. Teitelbaum · 2007 · Science
  23. Gene therapy: a viable therapeutic strategy for Parkinson’s disease?
    Alexander L. Berry, Thomas Foltynie · 2010 · Journal of Neurology
  24. Focal, remote-controlled, chronic chemical modulation of brain microstructures
    Khalil B. Ramadi, Canan Dağdeviren, Kevin C. Spencer, Pauline Joe, Max J. Cotler, Erin B. Rousseau, Carlos Nunez-Lopez, Ann M. Graybiel, Róbert Langer, Michael J. Cima · 2018 · Proceedings of the National Academy of Sciences
  25. Cell reprogramming approaches in gene- and cell-based therapies for Parkinson's disease
    Jodie H.K. Man, Lucianne Groenink, Massimiliano Caiazzo · 2018 · Journal of Controlled Release
  26. Beneficial Effects on Brain Micro-Environment by Caloric Restriction in Alleviating Neurodegenerative Diseases and Brain Aging
    Li Zhang, Huachong Xu, Ning Ding, Xue Li, Xiaoyin Chen, Zhuangfei Chen · 2021 · Frontiers in Physiology
  27. Intrathecal granulocyte colony-stimulating factor modulate glial cell line-derived neurotrophic factor and vascular endothelial growth factor A expression in glial cells after experimental spinal cord ischemia
    Chun‐Hong Chen, Shiying Huang, N.-F. Chen, Chien‐Wei Feng, Han-Chun Hung, Chun-Sung Sung, Yen‐Hsuan Jean, Zhi‐Hong Wen, W.-F. Chen · 2013 · Neuroscience
  28. Distribution and immunohistochemical localization of GDNF protein in selected neural and non-neural tissues of rats during development and changes in unilateral 6-hydroxydopamine lesions
    Ritsuko Katoh‐Semba, Masako Tsuzuki, Noriko Miyazaki, Akiko Yoshida, Hidemitsu Nakajima, Chiaki W. Nakagawa, Satoko Kitajima, Motoko Matsuda · 2007 · Neuroscience Research
  29. Prospects for gene therapy in inherited neurodegenerative diseases
    Monica Cardone · 2007 · Current Opinion in Neurology
  30. Transplantation of NGF secreting primary monocytes counteracts NMDA-induced cell death of rat cholinergic neurons in vivo
    Birgit Zassler, Christian Humpel · 2006 · Experimental Neurology
  31. An Update on Gene Therapy in Parkinson’s Disease
    Jennifer L. Witt, William J. Marks · 2011 · Current Neurology and Neuroscience Reports
  32. Neuroprotection and imaging studies in Parkinson's disease
    Nicola Pavese, Lorenzo Kiferle, Paola P. Piccini · 2009 · Parkinsonism & Related Disorders
  33. Induction of Neurorestoration from Endogenous Stem Cells
    J. Yu, J. Seo, Ji-Yong Lee, Min-Young Lee, Sung-Rae Cho · 2016 · Cell Transplantation
  34. Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement
    Jonas Hjelmgren, Ola Ghatnekar, Jan Reimer, Martin Grabowski, Olle Lindvall, Ulf Persson, Peter Hagell · 2006 · Parkinsonism & Related Disorders
  35. Targeted gene transfer to nigrostriatal neurons in the rat brain by helper virus-free HSV-1 vector particles that contain either a chimeric HSV-1 glycoprotein C-GDNF or a gC-BDNF protein
    Xiaodan Wang, Lingxin Kong, Guorong Zhang, Mei Sun, Alfred I. Geller · 2005 · Molecular Brain Research
  36. Sonic hedgehog delivered by an adeno-associated virus protects dopaminergic neurones against 6-OHDA toxicity in the rat
    B. Dass, Mahmoud M. Iravani, Chi-Shuan Huang, James Barsoum, Thomas M. Engber, Alphonse Galdes, Peter G. Jenner · 2004 · Journal of Neural Transmission
  37. Adult Stem Cell Treatments for Diseases?
    Shane D. B. Smith, William B. Neaves, Steven L. Teitelbaum · 2006 · Science
  38. Role of surgery in the treatment of motor complications
    Leo Verhagen Metman, Shaun T. O’Leary · 2005 · Movement Disorders
  39. The Proform of Glia Cell Line-Derived Neurotrophic Factor: a Potentially Biologically Active Protein
    Xiaolong Sun, Bei‐Yu Chen, Li Na Duan, Yi Xia, Zhuo-Jing Luo, Jingjie Wang, Zhi‐Ren Rao, Liang-Wei Chen · 2013 · Molecular Neurobiology
  40. Adenoviral-Mediated Glial Cell Line–Derived Neurotrophic Factor Gene Transfer Has a Protective Effect on Sciatic Nerve Following Constriction-Induced Spinal Cord Injury
    An‐Kuo Chou, Ming‐Chang Yang, Hung‐Pei Tsai, Chee‐Yin Chai, Ming‐Hong Tai, Aij-Li Kwan, Yi‐Ren Hong · 2014 · PLoS ONE
  41. Effects of intracerebral neurotrophic factor application on motor symptoms in Parkinson's disease: A systematic review and meta-analysis
    Shane Vincent Hegarty, David J. Lee, Gerard W. O’Keeffe, Aideen M. Sullivan · 2017 · Parkinsonism & Related Disorders
  42. Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models
    Rong Zhang, Ryuta Saito, Yui Mano, Akira Sumiyoshi, Masayuki Kanamori, Yukihiko Sonoda, Ryuta Kawashima, Teiji Tominaga · 2015 · Drug Delivery
  43. Polymer-coated cannulas for the reduction of backflow during intraparenchymal infusions
    Louis C. Vazquez, Erik Hagel, Bradley Jay Willenberg, Wei Dai, Fernando Casanova, Christopher D. Batich, Malisa Sarntinoranont · 2012 · Journal of Materials Science Materials in Medicine
  44. Addressing Neurological Disorders With Neuromodulation
    Chima O. Oluigbo, Ali R. Rezai · 2011 · IEEE Transactions on Biomedical Engineering
  45. Intrastriatal GDNF gene transfer by inducible lentivirus vectors protects dopaminergic neurons in a rat model of parkinsonism
    Shasha Chen, Chun Yang, Fei Hao, Chen Li, Tao Lu, Li‐Ru Zhao, Wei‐Ming Duan · 2014 · Experimental Neurology
  46. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease
    Hiromi Sano, Miho Murata, Atsushi Nambu · 2015 · Journal of Neurochemistry
  47. Effects of aging on glutamate neurotransmission in the substantia nigra of Gdnf heterozygous mice
    Ariana Q. Farrand, Rebecca A. Gregory, Michael D. Scofield, Kristi L. Helke, Heather A. Boger · 2014 · Neurobiology of Aging
  48. Brain Drug Delivery Systems for Neurodegenerative Disorders
    Elisa Garbayo, Eduardo Ansorena, María J. Blanco‐Prieto · 2012 · Current Pharmaceutical Biotechnology
  49. Gene therapy approaches in the non-human primate model of Parkinson’s disease
    Diego Pignataro, Diego Sucunza, Alberto J. Rico, Iria G. Dopeso‐Reyes, Elvira Roda, Ana Isabel Rodriguez-Perez, José Luis Labandeira-García, Vania Broccoli, Shigeki Kato, Kazuto Kobayashi et al. · 2017 · Journal of Neural Transmission
  50. Long-Term Non-Invasive Treatment via Intranasal Administration of Nerve Growth Factor Protects the Human Brain in Frontotemporal Dementia associated with Corticobasal Syndrome: A Pilot Study
    Alberto de Bellis, Massimo de Bellis, Luigi Aloe · 2018 · Journal of Alzheimer s Disease Reports
  51. Electroacupuncture therapy ameliorates motor dysfunction via brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease
    Malk Eun Pak, Sung‐Min Ahn, Da Hee Jung, Hong Ju Lee, Ki Tae Ha, Hwa Kyoung Shin, Byung Tae Choi · 2019 · The Journals of Gerontology Series A
  52. Future Applications: Gene Therapy
    Robert Mark Richardson, Vanja Varenika, John Forsayeth, Krystof S. Bankiewicz · 2009 · Neurosurgery Clinics of North America
  53. Tetanus toxin fragment C fusion facilitates protein delivery to CNS neurons from cerebrospinal fluid in mice
    Susanna C. Benn, İlknur Ay, Elena Bastia, Ru-Ju Chian, Samuel A. Celia, R. Blake Pepinsky, Paul S. Fishman, Robert H. Brown, Jonathan W. Francis · 2005 · Journal of Neurochemistry
  54. Potential cellular and regenerative approaches for the treatment of Parkinson’s disease
    Emma L. Lane, Stephen B. Dunnett, Anne Rosser · 2008 · Neuropsychiatric Disease and Treatment
  55. Cell transplantation for Parkinson's disease
    Ben Zion Roitberg, Klaudia Urbaniak, Marina Elena Emborg · 2004 · Neurological Research
  56. Convection-enhanced delivery of AAV2 in white matter—A novel method for gene delivery to cerebral cortex
    Neil U. Barua, Max Woolley, Ali Bienemann, D. Johnson, Marcella J. Wyatt, Charlie Irving, Owen T. Lewis, Emma S. Castrique, Steven S. Gill · 2013 · Journal of Neuroscience Methods
  57. Effects of striatal transplantation of cells transfected with GDNF gene without pre- and pro-regions in mouse model of Parkinson’s disease
    Alexander V. Revishchin, L. S. Moiseenko, N. N. Kust, N. Bazhenova, P. Teslia, Dmitry Y. Panteleev, Vladimir M. Kovalzon, Galina Valerievna Pavlova · 2016 · BMC Neuroscience
  58. Role of Glial Cell Line‐Derived Neurotrophic Factor in the Maintenance of Adult Mesencephalic Catecholaminergic Neurons
    Daniel Enterría‐Morales, Ivette López‐López, José López‐Barneo, Xavier d’Anglemont de Tassigny · 2020 · Movement Disorders
  59. Neurotrophins as Therapeutic Agents for Parkinson’s Disease; New Chances From Focused Ultrasound?
    Alessandro Stefani, Mariangela Pierantozzi, Silvia Cardarelli, Lucrezia Stefani, Rocco Cerroni, Matteo Conti, Elena Garasto, Nicola Biagio Mercuri, Carmine Marini, Patrizia Sucapane · 2022 · Frontiers in Neuroscience
  60. Current controversies in Niemann–Pick C1 disease: steroids or gangliosides; neurons or neurons and glia
    Robert P. Erickson · 2013 · Journal of Applied Genetics
  61. Encapsulated cell-based biodelivery of Meteorin is neuroprotective in the quinolinic acid rat model of neurodegenerative disease
    Jens Tornøe, Malene Torp, Jesper Roland Jørgensen, Dwaine F. Emerich, Chris G. Thanos, Briannan E. Bintz, Lone Fjord‐Larsen, Lars U. Wahlberg · 2012 · Restorative Neurology and Neuroscience
  62. Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats
    Juho‐Matti Renko, Arun Kumar Mahato, Tanel Visnapuu, Konsta Valkonen, Mati M. Karelson, Merja H. Voutilainen, Märt Saarma, Raimo K. Tuominen, Yulia A. Sidorova · 2021 · Journal of Parkinson s Disease
  63. The Impact of Neurotechnology on Rehabilitation
    T. Berger, G. Gerhardt, M. Liker, W. Soussou · 2008 · IEEE Reviews in Biomedical Engineering
  64. Invited review: Utilizing peripheral nerve regenerative elements to repair damage in the CNS
    Nader El Seblani, Andrew S. Welleford, Jorge E. Quintero, Craig G. van Horne, Greg A. Gerhardt · 2020 · Journal of Neuroscience Methods
  65. RNAi Therapy for Neurodegenerative Diseases
    Ryan L. Boudreau, Beverly L. Davidson · 2006 · Current topics in developmental biology/Current Topics in Developmental Biology
  66. Neurodegenerative movement disorders: the contribution of functional imaging
    P. Piccini · 2004 · Current Opinion in Neurology
  67. The effect of resistance exercise upon age-related systemic and local skeletal muscle inflammation
    A.K. Ziegler, S.M. Jensen, Peter Schjerling, Abigail Louise Mackey, Jesper L. Andersen, Michael Kjær · 2019 · Experimental Gerontology
  68. Evaluation and Optimization of the Administration of Recombinant Adeno-Associated Viral Vectors (Serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by Convection-Enhanced Delivery to the Striatum
    Edward White, Alison S. Bienemann, Miguel Sena‐Esteves, Hannah Taylor, Chotirote Bunnun, Emma S. Castrique, Steven S. Gill · 2010 · Human Gene Therapy
  69. Constitutive Ret signaling is protective for dopaminergic cell bodies but not for axonal terminals
    Jelena Mijatovic, Marjo Piltonen, Paolo Alberton, Pekka T. Männistö, Märt Saarma, Petteri T. Piepponen · 2009 · Neurobiology of Aging
  70. Proliferar ou diferenciar? Perspectivas de destino das células-tronco
    Schwindt TT, Gabriela Filoso Barnabé, Mello Leam · 2018 · JBNC - JORNAL BRASILEIRO DE NEUROCIRURGIA
  71. Peripheral Gene Transfer of Glial Cell-Derived Neurotrophic Factor Ameliorates Neuropathic Deficits in Diabetic Rats
    Guei‐Sheung Liu, Jhih-Yin Shi, Chiou‐Lian Lai, Yi‐Ren Hong, Shyi-Jang Shin, Hung‐Tu Huang, Hing‐Chung Lam, Zhi‐Hong Wen, Kuei‐Sen Hsu, Chih‐Hao Chen et al. · 2009 · Human Gene Therapy
  72. Therapeutic strategies for neurodegenerative disorders: Emerging clues from parkinson's disease
    Carsten Reidies Bjarkam, Jens Christian Hedemann Sørensen · 2004 · Biological Psychiatry
  73. New Therapeutic Approaches to Parkinson’s Disease Including Neural Transplants
    Wei‐Li Kuan, RogerA Barker · 2005 · Neurorehabilitation and neural repair
  74. Biomarkers for trials of neuroprotection in Parkinson's disease
    Pankaj Ashok Agarwal, A. Jon Stoessl · 2012 · Movement Disorders
  75. Association between epidermal growth factor receptor gene polymorphisms and susceptibility to Parkinson’s disease
    Jianing Jin, Xue Li, Xinling Bai, Xiaona Zhang, Qingwu Tian, Anmu Xie · 2020 · Neuroscience Letters
  76. Small Molecules and Peptides Targeting Glial Cell Line-Derived Neurotrophic Factor Receptors for the Treatment of Neurodegeneration
    Yulia A. Sidorova, Märt Saarma · 2020 · International Journal of Molecular Sciences
  77. Is activation of GDNF/RET signaling the answer for successful treatment of Parkinson’s disease? A discussion of data from the culture dish to the clinic
    Edgar R. Kramer, James A. Conway · 2021 · Neural Regeneration Research
  78. Neuroprotective approaches to halt Parkinson's disease progression
    Piyong Sola, Praveen Thaggikuppe Krishnamurthy, Mamta Kumari, Gowramma Byran, Hosahalli Veerabhadrappa Gangadharappa, Kusuma Kumari Garikapati · 2022 · Neurochemistry International
  79. Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications.
    R. Kuriakose, A. Stoessl · 2010 · Progress in Brain Research
  80. Astrocytes Role in Parkinson: A Double-Edged Sword
    Ricardo Cabezas, Marco Fidel, Daniel Torrente, Ramon dos Santos El-Bachá, Ludis Morales, Janneth González, George E. · 2013 · InTech eBooks
  81. Gene Therapy for Parkinsons and Alzheimers Diseases: from the Bench to Clinical Trials
    Rui Jorge Nobre, Luís Pereira de Almeida · 2011 · Current Pharmaceutical Design
  82. GDNF is important for striatal organization and maintenance of dopamine neurons grown in the presence of the striatum
    Maria Chermenina, P. Schouten, Nina Nevalainen, F. Johansson, Greger Orädd, Ingrid Strömberg · 2014 · Neuroscience
  83. Advances in Neurotrophic Factor and Cell-Based Therapies for Parkinson's Disease: A Mini-Review
    Michael D. Staudt, Andrea R. Di Sebastiano, Hu Xu, Mandar Jog, Susanne Schmid, Paula J. Foster, Matthew O. Hebb · 2015 · Gerontology
  84. Transgenic Expression of Human Glial Cell Line-Derived Neurotrophic Factor from Integration-Deficient Lentiviral Vectors is Neuroprotective in a Rodent Model of Parkinson's Disease
    Ngoc Lu‐Nguyen, Martin Broadstock, Maximilian G. Schliesser, Cynthia C. Bartholomae, Christof V. Kalle, Manfred Schmidt, Rafael J. Yáñez‐Muñoz · 2014 · Human Gene Therapy
  85. Convection-enhanced Delivery of Therapeutics for Malignant Gliomas
    Ryuta Saito, Teiji Tominaga · 2016 · Neurologia medico-chirurgica
  86. Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration
    Khalid Bashir Dar, Aashiq Hussain Bhat, Shajrul Amin, Bilal Ahmad Reshi, Mohammad Afzal Zargar, Akbar Masood, Showkat Ahmad Ganie · 2019 · Cellular and Molecular Neurobiology
  87. The role of neurotrophic factors in the pathology and treatment of multiple sclerosis
    Dagmara Maria Mirowska-Guzel · 2008 · Immunopharmacology and Immunotoxicology
  88. Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease
    Mallory J. Stenslik, Lisa F. Potts, James Sonne, Wayne A. Cass, Jadwiga T. Turchan-Cholewo, François Pomerleau, Peter F. Huettl, Yi Ai, Don Marshall Gash, Greg A. Gerhardt et al. · 2015 · Journal of Neuroscience Methods
  89. Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP+ toxicity by GDNF
    Birthe Jakobsen, Jan Bert Gramsbergen, Annette Møller Dall, Carl Rosenblad, Jens Zimmer · 2005 · European Journal of Neuroscience
  90. Experimental therapies for Parkinson's disease: Why fake it?
    Alla Katsnelson · 2011 · Nature
  91. Self-Assembled Nanoscale Materials for Neuronal Regeneration: A Focus on BDNF Protein and Nucleic Acid Biotherapeutic Delivery
    Yu Wu, Miora Rakotoarisoa, Borislav Angelov, Yuru Deng, Angelina Angelova · 2022 · Nanomaterials
  92. Fiberoptic microneedle device facilitates volumetric infusate dispersion during convection‐enhanced delivery in the brain
    R. Lyle Hood, Rudy T. Andriani, Samantha Emch, John L. Robertson, Christopher G. Rylander, John Henry Rossmeisl · 2013 · Lasers in Surgery and Medicine
  93. Potential therapeutic targets for Parkinson's disease
    A. Jon Stoessl · 2008 · Expert Opinion on Therapeutic Targets
  94. Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson’s disease
    Hironori Yokoyama, Hayato Kuroiwa, Jiro Kasahara, Tsutomu Araki · 2011 · Acta Neurobiologiae Experimentalis
  95. Implantation of autologous peripheral nerve grafts into the substantia nigra of subjects with idiopathic Parkinson's disease treated with bilateral STN DBS: a report of safety and feasibility
    Craig G. van Horne, Jorge E. Quintero, Julie A. Gurwell, Renee P. Wagner, John T. Slevin, Greg A. Gerhardt · 2016 · Journal of neurosurgery
  96. Glial cell line-derived neurotrophic factor family ligands and their therapeutic potential
    Yulia A. Sidorova, Märt Saarma · 2016 · Molecular Biology
  97. Is GDNF beneficial in Parkinson disease?
    Barry J. Hoffer, Brandon K. Harvey · 2011 · Nature Reviews Neurology
  98. Combination of Human Mesenchymal Stem Cells and Repetitive Transcranial Magnetic Stimulation Enhances Neurological Recovery of 6-Hydroxydopamine Model of Parkinsonian’s Disease
    Ji Yong Lee, Hyun Soo Kim, Sung Hoon Kim, Han-Soo Kim, Byung Pil Cho · 2020 · Tissue Engineering and Regenerative Medicine
  99. GDNF modulates HO-1 expression in substantia nigra postnatal cell cultures
    Ana Saavedra, Graça Baltazar, Caetana M. Carvalho, Emı́lia P. Duarte · 2005 · Free Radical Biology and Medicine
  100. Histological Effects of Intraputaminal Infusion of Glial Cell Line-Derived Neurotrophic Factor in Parkinson Disease Model Macaque Monkeys
    Yoshitsugu Oiwa, Kunio NAKAI, Toru Itakura · 2006 · Neurologia medico-chirurgica